Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00047216
Status:
COMPLETED
Last Update Posted:
2015-07-23
First Post:
2002-10-03
Brief Title:
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
A Phase II Study of R115777 Zarnestra in Superficial Transitional Cell Carcinoma of Bladder
Status:
COMPLETED
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
PURPOSE Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent bladder cancer
PURPOSE Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent bladder cancer
Detailed Description:
OBJECTIVES
Determine the 1-year recurrence-free survival rate of patients with stage 0 or I recurrent transitional cell carcinoma of the bladder treated with tipifarnib
OUTLINE This is a multicenter study
Patients receive oral tipifarnib twice daily on days 1-21 Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months
PROJECTED ACCRUAL A total of 37 patients will be accrued for this study within 18 months
Determine the 1-year recurrence-free survival rate of patients with stage 0 or I recurrent transitional cell carcinoma of the bladder treated with tipifarnib
OUTLINE This is a multicenter study
Patients receive oral tipifarnib twice daily on days 1-21 Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months
PROJECTED ACCRUAL A total of 37 patients will be accrued for this study within 18 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-5612 | Registry Identifier | PDQ Physician Data Query | None |
| CDR0000257564 | REGISTRY | None | None |